Significant number of drugs on the market not yet fully approved
A large number of drug manufacturers are failing to complete the FDA’s Accelerated Approval Program, meaning not all available drugs are fully approved, finds a study.
The INFORMS Analytics+ Conference showcased how companies are turning advanced analytics and AI into measurable operational results
In most emergency departments, beds are a hot commodity. But some patients don’t actually need a bed for their treatment – and accurately identifying those people is a low-lift but effective way to increase efficiency without sacrificing care quality, finds a study recently published in the journal Management Science.
The researchers developed a simple decision tree, informed by mathematical and machine learning models, to help staff decide whether a patient truly needs a bed or can be routed to a “vertical processing pathway” – that is, an area where they can be treated sitting up. Many hospitals already have such an area but don’t necessarily have a systematic way to decide which patients are treated there.
Diversity alone won’t get the votes for funding public education. It takes communities that are more integrated and connected, where residents have a sense of shared stake.
An audio journey of how data and analytics save lives, save money and solve problems.

Jeff Cohen
Chief Strategy Officer
INFORMS
Catonsville, MD
[email protected]
443-757-3565
Explore our resources for multiple topics including:
A large number of drug manufacturers are failing to complete the FDA’s Accelerated Approval Program, meaning not all available drugs are fully approved, finds a study.
The Food and Drug Administration (FDA) Accelerated Approval Program was created in 1992 to considerably speed up the ability to bring certain new drugs to market. Further research to be revealed in upcoming issues of the INFORMS journal Manufacturing & Service Operations Management shows numerous drug producers are failing to finish the approval course of, meaning a significant number of drugs on the market will not be but approved.
Colorectal cancer (CRC) is the second leading cause of death due to cancer in the United States. Regular medical screening can be effective in detection and treatment, but only about 40 percent of the population is doing it. So why would people risk a potentially deadly diagnosis? Research points to significant appointment delays among some of the most effective tests, such as a colonoscopy.
CATONSVILLE, MD, August 26, 2019 – The Food and Drug Administration’s (FDA) Accelerated Approval Program was created in 1992 to significantly accelerate the ability to bring certain new drugs to market. New research published in the INFORMS journal Manufacturing & Service Operations Management reveals a large number of drug manufacturers are failing to complete the approval process, meaning a significant number of drugs on the market are not yet fully approved.
Hospitals can seem like confusing, chaotic places for patients, even when the employees are following well-established protocols and resource management techniques. But there is always room for improvement. That’s the goal behind the research of Hummy Song, Wharton professor of operations, information and decisions, who focuses on improving the performance of health care delivery systems.

OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today Magazine
Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine